Escin (also known as aescin), the primary component of horse chestnut seed extract (HCSE), is a mixture of triterpene saponins present in alpha and beta forms, distinguished by their different levels of water solubility and melting points. It is indicated in adults for the treatment of chronic venous insufficiency and its associated symptoms, which include swelling of the lower limbs, varices, pain (generalized), feelings of weight of the lower limbs, itching, feelings of tension and cramps in the calves.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
Please note: Due to the complexity and amount of studies regarding this compound—a Natural Health Product—increased cost is charged.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Escin, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.